Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 14, 2024
Data Byte
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP
November meeting highlights also include a pair of firsts for rare genetic diseases, and label expansions for eight approved drugs
BioCentury | Jul 17, 2024
Data Byte
FDA’s five NME approvals in June bring 1H24 total to 21
Ipsen’s Iqirvo, Geron’s Rytelo among June highlights
BioCentury | Jun 7, 2024
Regulation
At long last, Geron wins FDA approval of first drug
The 34-year-old company will bring to market Rytelo imetelstat for some patients with myelodysplastic syndromes
BioCentury | Jan 27, 2024
Discovery & Translation
Genentech’s i-shaped Abs; a bispecific dendritic-T cell engager and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 6, 2023
Finance
Sept. 6 Quick Takes: Patient Square again fuels Apollo’s mission in $226.5M series C
Plus: Astellas drops IRA lawsuit after CMS passes on Xtandi and updates on Ultomiris, Rybrevant, exo-cel, Tentarix, Rejuvenation, and more
BioCentury | Aug 22, 2023
Finance
Aug. 22 Quick Takes: Forty51-backed Mysthera launches to development autoimmune therapies
Plus: FDA lifts hold on Fulcrum’s trial and more, panel to discuss Geron’s imetelstat
BioCentury | Jan 5, 2023
Product Development
Jan. 4 Quick Takes: Roivant TL1A mAb heading into Phase III in ulcerative colitis
Plus: 16 years on, Geron forges ahead with imetelstat and updates from NextPoint, Moderna, Hummingbird-Synaffix and more
BioCentury | Jun 16, 2022
Management Tracks
Dealhoy becomes CBO at Deciphera
Plus new CSO at GlycoEra, and updates from Geron, Ysios, CBC and more
BioCentury | Oct 23, 2021
Product Development
Gene therapy’s next class of biotechs
And the innovative technologies they’re developing
BioCentury | Mar 6, 2021
Product Development
The pace of new modality approvals is picking up
Close to 30 new modality drugs approved in the last five years, and about 50 in registrational trials
Items per page:
1 - 10 of 408